Alexandre Cinq-Mars, Montse Massot, David Belzile, Pierre Yves Turgeon, Sacha-Michelle Dubois-Sénéchal, Claudine Laliberté, Marie-Ève Komlosy, Marie-Hélène Leblanc, Sébastien Bergeron, Kim O'Connor, Joëlle Morin, Christine Bourgault, Mathieu Bernier, Jonathan Beaudoin, Steve Radermaker, Maxime Laflamme, Eric Charbonneau, Mario Sénéchal
BACKGROUND: Dilated cardiomyopathy (DCM) is a well described entity for heart failure (HF) with reduced left ventricular ejection fraction (LVEF). Recently, drugs and other substance of abuse have been recognised as potential triggers for DCM. The aim of this study was to assess the survival in patients ≤ 65 years of age with toxic cardiomyopathy (TCM). Left ventricular remodelling and the potential usefulness of left ventricular assist devices (LVADs) was also assessed. METHODS: This was a single-centre retrospective study from January 2003 to August 2019 of 553 patients ≤ 65 years old with LVEF < 40% at a tertiary-care cardiology centre...
November 11, 2021: Canadian Journal of Cardiology